Q-omics provides the consensus-scored TMEM26 profile across patient tissues and cancer cell-line models. TMEM26 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TMEM26 is differentially expressed in 9, with the highest sampling consensus in HNSC. Additionally, TMEM26 RNA expression shows 18,151 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, HNSC, and GBM as cancer lineages where TMEM26 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM26 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM26 survival associations across molecular data types. TMEM26 RNA expression shows survival associations in the most cancer types (16), followed by mutation status (4) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM26 RNA expression–survival associations across cancer types. High TMEM26 expression shows unfavorable associations in THCA, LGG and DLBC, but favorable associations in KIRC, BRCA and HNSC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TMEM26 RNA expression.
This table summarizes TMEM26 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 1. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TMEM26. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM26 shows lower tumor expression in KICH and LIHC and higher tumor expression in HNSC, KIRC, BLCA and STAD. The HNSC box plot shows higher TMEM26 RNA expression in tumor versus normal tissue (log2 FC = +0.532, t-test p < 0.001).
This table shows molecular features associated with TMEM26 in patient tissues and cancer cell lines. In patient samples, TMEM26 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM26 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and CNS.
